Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Carpipramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 9/20 | 0.94 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.94 |
| ▸ | CHRM2 known ✓ | P08172 | 3/20 | 0.94 |
| ▸ | CHRM1 known ✓ | P11229 | 3/20 | 0.94 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.94 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.94 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.94 |
| ▸ | OPRM1 known ✓ | P35372 | 2/20 | 0.94 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.94 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.94 |
| ▸ | DRD4 known ✓ | P21917 | 8/20 | 0.45 |
| ▸ | DRD2 known ✓ | P14416 | 7/20 | 0.45 |
| ▸ | CHRM4 known ✓ | P08173 | 2/20 | 0.44 |
| ▸ | CHRM5 known ✓ | P08912 | 2/20 | 0.44 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.44 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.43 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.43 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 2/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carpipramine SCHEMBL7353292 | 0.98 | DRD3 (0.98) | DRD3ADRA1ACHRM2CHRM1HTR1A | |
| Carpipramine SCHEMBL969082 | 0.97 | DRD3 (0.96) | DRD3ADRA1ACHRM2CHRM1HTR1A | |
| Carpipramine SCHEMBL29356300 | 0.97 | DRD3 (0.96) | DRD3ADRA1ACHRM2CHRM1HTR1A | |
| Carpipramine SCHEMBL17747956 | 0.97 | DRD3 (0.96) | DRD3ADRA1ACHRM2CHRM1HTR1A | |
| Carpipramine SCHEMBL17747957 | 0.97 | DRD3 (0.96) | DRD3ADRA1ACHRM2CHRM1HTR1A | |
| Carpipramine SCHEMBL34949 | 0.97 | DRD3 (1.00) | DRD3ADRA1ACHRM2CHRM1HTR1A | |
| Carpipramine SCHEMBL27478838 | 0.97 | DRD3 (1.00) | DRD3ADRA1ACHRM2CHRM1HTR1A | |
| Carpipramine SCHEMBL29913255 | 0.97 | DRD3 (1.00) | DRD3ADRA1ACHRM2CHRM1HTR1A | |
| Carpipramine SCHEMBL969084 | 0.96 | DRD3 (0.98) | DRD3ADRA1ACHRM2CHRM1HTR1A | |
| Carpipramine SCHEMBL365672 | 0.96 | DRD3 (0.98) | DRD3ADRA1ACHRM2CHRM1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| CN-101119715-A | SPM 927 for add-on therapy of schizophrenia | SANOL ARZNEI SCHWARZ GMBH (DE) | 2008-02-06 | — | — | CN | disclosed |
| US-20060252749-A1 | Lacosamide for add-on therapy of psychosis | SRZ PROPERTIES, INC. (US) | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252749-A1 | Lacosamide for add-on therapy of psychosis | SLC6A11, SLC6A3, SLC6A1 | DRD3 149/4885ADRA1A 1133/4885CHRM2 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.